Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen

被引：12
|
作者：
Liew, Elena [1 ]
Atenafu, Eshetu G. [2 ]
Schimmer, Aaron D. [1 ]
Yee, Karen W. L. [1 ]
Schuh, Andre C. [1 ]
Minden, Mark D. [1 ]
Gupta, Vikas [1 ]
Brandwein, Joseph M. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Princess Margaret Hosp, Dept Biostat, Toronto, ON M5G 2M9, Canada
来源：
LEUKEMIA RESEARCH | 2012年 / 36卷 / 12期
关键词：
Leukemia; Lymphoblastic; Acute; Chemotherapy; Allogeneic stem cell transplantation; MINIMAL RESIDUAL DISEASE; STANDARD-RISK; THERAPY; MRD; AGE;
D O I：
10.1016/j.leukres.2012.08.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We analyzed the outcome of 46 patients with acute lymphoblastic leukemia (ALL) who relapsed following treatment with a pediatric-based protocol; 34 received intensive re-induction chemotherapy, with a CR2 rate of 62%, median overall survival (OS) 7.8 months, median relapse-free survival 5.2 months and one year OS 19%. Allogeneic HSCT was performed in 8 patients in CR2/3, with a median OS 2.2 months. OS was superior in patients who relapsed after completion of chemotherapy, compared to those relapsing on treatment. The outcome of adult ALL relapsing after treatment was therefore poor, and novel salvage strategies are needed to improve outcomes. (C) 2012 Published by Elsevier Ltd.
引用
收藏
页码：1517 / 1520
页数：4
相关论文
共 50 条
  • [1] A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China
    Gong, Xiaoyuan
    Fang, Qiuyun
    Gu, Runxia
    Qiu, Shaowei
    Liu, Kaiqi
    Lin, Dong
    Zhou, Chunlin
    Zhang, Guangji
    Gong, Benfa
    Liu, Yuntao
    Li, Yan
    Liu, Bingcheng
    Wang, Ying
    Wei, Hui
    Mi, Yingchang
    Wang, Jianxiang
    HAEMATOLOGICA, 2024, 109 (10) : 3146 - 3156
  • [2] Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia
    Sucre, Oscar
    Pamulapati, Saagar
    Muzammil, Zeeshan
    Bitran, Jacob
    CELLS, 2025, 14 (05)
  • [3] Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia
    Yeoh, Amelia
    Collins, Anna
    Fox, Kahlia
    Shields, Sarah
    Ritchie, Petra
    Kirby, Maria
    Revesz, Tamas
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (01) : 38 - 42
  • [4] Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
    Paul, Shilpa
    Rausch, Caitlin R.
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03) : 166 - 175
  • [5] Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
    Pourhassan, Hoda
    Agrawal, Vaibhav
    Pullarkat, Vinod
    Aldoss, Ibrahim
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol
    Liew, Elena
    Thyagu, Santhosh
    Atenafu, Eshetu G.
    Alibhai, Shabbir M. H.
    Brandwein, Joseph M.
    LEUKEMIA RESEARCH, 2013, 37 (12) : 1632 - 1635
  • [7] Treatment of Adult Acute Lymphoblastic Leukemia
    Goekbuget, Nicola
    Hoelzer, Dieter
    SEMINARS IN HEMATOLOGY, 2009, 46 (01) : 64 - 75
  • [8] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
    Wakase, Shiho
    Teshima, Takanori
    Zhang, Jie
    Ma, Qiufei
    Watanabe, Yoko
    Yang, Hongbo
    Qi, Cynthia Z.
    Chai, Xinglei
    Xie, Yanwen
    Wu, Eric Q.
    Igarashi, Ataru
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 241.e1 - 241.e11
  • [9] Oral Mucositis in Pediatric Patients in Treatment for Acute Lymphoblastic Leukemia
    Arrais Ribeiro, Isabella Lima
    Tolentino Limeira, Rebecca Rhuanny
    de Castro, Ricardo Dias
    Ferreti Bonan, Paulo Rogerio
    Gondim Valenca, Ana Maria
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2017, 14 (12)
  • [10] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Marks, David, I
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    Jabbour, Elias
    Merchant, Akil
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop
    O'Brien, Susan
    BLOOD CANCER JOURNAL, 2020, 10 (08)
12345